Your session is about to expire
← Back to Search
Mucolytic Agent
N-acetyl cysteine then Placebo for Idiopathic Pulmonary Fibrosis
Phase 1 & 2
Waitlist Available
Led By Mark Steele, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 10, and week 18
Awards & highlights
Summary
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.
Eligible Conditions
- Idiopathic Pulmonary Fibrosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 10, and week 18
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 10, and week 18
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in Pulmonary function - DLCO
Changes in Pulmonary function - FVC
Trial Design
2Treatment groups
Experimental Treatment
Group I: Placebo then N-acetyl cysteineExperimental Treatment1 Intervention
This arm will receive placebo followed by NAC
Group II: N-acetyl cysteine then placeboExperimental Treatment1 Intervention
This arm will receive NAC followed by placebo
Find a Location
Who is running the clinical trial?
University of Colorado, DenverLead Sponsor
1,791 Previous Clinical Trials
2,788,075 Total Patients Enrolled
3 Trials studying Idiopathic Pulmonary Fibrosis
9,000 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Mark Steele, MDPrincipal InvestigatorUniversity of Colorado, Denver
Share this study with friends
Copy Link
Messenger